Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.49M Buy
4,005
+90
+2% +$30.8K 0.32% 68
2026
Q1
$1.29M Buy
3,915
+399
+11% +$142K 0.29% 84
2025
Q4
$1.22M Buy
3,516
+457
+15% +$145K 0.3% 76
2025
Q3
$893K Buy
3,059
+60
+2% +$17.4K 0.23% 100
2025
Q2
$890K Sell
2,999
-19
-0.6% -$5.38K 0.25% 93
2025
Q1
$849K Sell
3,018
-280
-8% -$82.7K 0.26% 95
2024
Q4
$908K Sell
3,298
-2,816
-46% -$835K 0.28% 78
2024
Q3
$1.97M Buy
6,114
+98
+2% +$32.1K 0.62% 30
2024
Q2
$2M Buy
6,016
+598
+11% +$176K 0.66% 25
2024
Q1
$1.44M Buy
5,418
+279
+5% +$81.6K 0.53% 37
2023
Q4
$1.53M Buy
5,139
+638
+14% +$174K 0.61% 29
2023
Q3
$1.17M Buy
4,501
+213
+5% +$53.2K 0.53% 33
2023
Q2
$1.13M Buy
+4,288
New +$995K 0.49% 39

Other funds holding AMGN

Guidance Capital's AMGN Position: Q2 2026 in Review

Guidance Capital increased its Amgen (AMGN) stake by 2.3% in Q2 2026, buying an estimated $30.8K and bringing the position to 4,005 shares worth $1.49M. The position accounts for 0.32% of the portfolio, ranked #68.

Guidance Capital first reported a position in AMGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $2M in Q2 2024. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Guidance Capital held 4,005 shares of Amgen worth $1.49M as of Q2 2026.
  • Guidance Capital bought 90 Amgen shares in Q2 2026, an estimated $30.8K.
  • Amgen made up 0.32% of Guidance Capital's portfolio in Q2 2026, its #68 holding.
  • Guidance Capital first reported a position in Amgen in Q2 2023 and has held it in 13 quarters since.
  • Guidance Capital's Amgen position peaked at $2M in Q2 2024.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Guidance Capital's 13F filing for Q2 2026, filed 20 Jul 2026.